Current Report Filing (8-k)
June 03 2022 - 08:55AM
Edgar (US Regulatory)
0001477845 false 0001477845 2022-06-02
2022-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 2, 2022
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in
Charter)
|
|
|
|
|
Delaware |
|
001-39202 |
|
26-2540421 |
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1055 Westlakes Drive,
Suite 300
Berwyn,
PA
19312
(Address of Principal Executive Offices, and Zip Code)
(610)
727-3913
Registrant’s Telephone Number, Including Area Code
Not
Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
ANVS |
New York Stock Exchange |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
¨ |
Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 |
Submission of Matters to
a Vote of Security Holders |
On June 2, 2022, Annovis Bio, Inc. (the “Company”) held its 2022
Annual Meeting of Stockholders (the “Annual Meeting”). All matters
voted upon at the Annual Meeting were approved with the required
votes. The matters that were voted upon at the Annual Meeting, and
the number of votes cast for or against, as well as the number of
abstentions and broker non-votes, as to each such matter are set
forth below.
1. Election of Directors.
The following director nominees were elected to serve as directors
of the Company, with the following votes tabulated:
|
|
For |
|
|
Withheld |
|
|
Broker Non-Vote |
|
Michael Hoffman |
|
|
3,294,037 |
|
|
|
152,137 |
|
|
|
2,249,648 |
|
Maria Maccecchini |
|
|
3,439,842 |
|
|
|
6,332 |
|
|
|
2,249,648 |
|
Claudine Bruck |
|
|
3,338,616 |
|
|
|
107,558 |
|
|
|
2,249,648 |
|
Reid McCarthy |
|
|
3,414,636 |
|
|
|
31,538 |
|
|
|
2,249,648 |
|
Mark White |
|
|
2,572,013 |
|
|
|
874,161 |
|
|
|
2,249,648 |
|
2. Ratification of the appointment of WithumSmith+Brown, PC as
our independent registered public accounting firm for the fiscal
year ending December 31, 2022.
The appointment of WithumSmith+Brown, PC as our independent
registered public accounting firm for the fiscal year ending
December 31, 2022 was ratified, with the following votes
tabulated:
For |
|
|
Against |
|
|
Abstain |
|
|
Broker Non-Vote |
5,674,126 |
|
|
5,920 |
|
|
15,776 |
|
|
- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ANNOVIS BIO,
INC. |
|
|
|
Date: June 3, 2022 |
By: |
/s/ Jeffrey McGroarty
|
|
|
Name: Jeffrey McGroarty |
|
|
Title: Chief Financial Officer |
Annovis Bio (AMEX:ANVS)
Historical Stock Chart
From May 2023 to Jun 2023
Annovis Bio (AMEX:ANVS)
Historical Stock Chart
From Jun 2022 to Jun 2023